Active, Not Recruiting
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Ironwood Cancer and Research Center Chandler, Arizona, United States
- UCLA HemOnc - Clinical Research Unit Los Angeles, California, United States
- Ridley-Tree Cancer Center Santa Barbara, California, United States
- PIH Health Whittier Hospital Whittier, California, United States